Keywords: Novo Nordisk, Degludec, EMA, Insulin, Type 1 and 2 diabetes, EU filing

Novo Nordisk files for EU approval of ultra-long-acting insulins Degludec and DegludecPlus

Article | 28 September 2011

Print This

Danish insulin giant Novo Nordisk NVO: N) has made the first regulatory approval submissions, to the European Medicines Agency, for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in